{"id":49494,"date":"2025-11-29T21:59:59","date_gmt":"2025-11-29T13:59:59","guid":{"rendered":"https:\/\/flcube.com\/?p=49494"},"modified":"2025-11-29T22:00:02","modified_gmt":"2025-11-29T14:00:02","slug":"pfizer-astellas-padcev-wins-fda-approval-for-perioperative-bladder-cancer","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=49494","title":{"rendered":"Pfizer-Astellas&#8217; PADCEV Wins FDA Approval for Perioperative Bladder Cancer"},"content":{"rendered":"\n<p><strong>Pfizer Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/PFE:NYSE\">NYSE: PFE<\/a>) and <strong>Astellas Pharma Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/4503:TYO\">TYO: 4503<\/a>) announced that the <strong>U.S. Food and Drug Administration (FDA)<\/strong> approved <strong>PADCEV (enfortumab vedotin)<\/strong> in combination with <strong>Keytruda (pembrolizumab)<\/strong> for <strong>perioperative treatment<\/strong> of adult patients with <strong>muscle\u2011invasive bladder cancer (MIBC)<\/strong> who are ineligible for cisplatin\u2011containing chemotherapy, based on the <strong>EV\u2011303\/KEYNOTE\u2011905 Phase\u202f3 trial<\/strong> showing a <strong>60% reduction<\/strong> in recurrence, progression, or death risk.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Product<\/strong><\/td><td>PADCEV (enfortumab vedotin) + Keytruda (pembrolizumab)<\/td><\/tr><tr><td><strong>Companies<\/strong><\/td><td>Pfizer (NYSE: PFE) &amp; Astellas (TYO: 4503)<\/td><\/tr><tr><td><strong>Agency<\/strong><\/td><td>U.S. Food and Drug Administration (FDA)<\/td><\/tr><tr><td><strong>Approval Type<\/strong><\/td><td>New indication (perioperative)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>MIBC (neoadjuvant + adjuvant) in cisplatin\u2011ineligible patients<\/td><\/tr><tr><td><strong>Study Basis<\/strong><\/td><td>EV\u2011303\/KEYNOTE\u2011905 Phase\u202f3 trial<\/td><\/tr><tr><td><strong>Primary Endpoint<\/strong><\/td><td>Event\u2011free survival (EFS)<\/td><\/tr><tr><td><strong>Result<\/strong><\/td><td>60% risk reduction vs. surgery alone<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile\">Drug Profile<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>PADCEV Mechanism:<\/strong> First\u2011in\u2011class <strong>Nectin\u20114 ADC<\/strong> delivering cytotoxic payload directly to tumor cells<\/li>\n\n\n\n<li><strong>Combination Strategy:<\/strong> Synergistic <strong>ADC + PD\u20111 inhibition<\/strong> enhances T\u2011cell activation and tumor cell killing<\/li>\n\n\n\n<li><strong>Global Approvals:<\/strong> Already approved for <strong>locally advanced\/metastatic urothelial cancer (la\/mUC)<\/strong> in the U.S., Japan, and other markets; EU approved for la\/mUC in platinum\u2011eligible patients; PADCEV monotherapy approved for la\/mUC post\u2011PD\u20111\/platinum<\/li>\n\n\n\n<li><strong>Innovation:<\/strong> First <strong>perioperative ADC\u2011IO regimen<\/strong> in bladder cancer, addressing pre\u2011 and post\u2011surgical treatment<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-evidence-ev-303-keynote-905-trial\">Clinical Evidence \u2013 EV\u2011303\/KEYNOTE\u2011905 Trial<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Endpoint<\/th><th>PADCEV + Keytruda vs. Surgery Alone<\/th><\/tr><\/thead><tbody><tr><td><strong>Primary (EFS)<\/strong><\/td><td><strong>60% risk reduction<\/strong> (HR\u202f=\u202f0.40)<\/td><\/tr><tr><td><strong>Event\u2011Free Probability<\/strong><\/td><td><strong>74.7%<\/strong> vs. <strong>39.4%<\/strong> at 12 months<\/td><\/tr><tr><td><strong>Median EFS<\/strong><\/td><td><strong>Not reached<\/strong> vs. <strong>15.7 months<\/strong><\/td><\/tr><tr><td><strong>Overall Survival (OS)<\/strong><\/td><td><strong>50% risk reduction<\/strong> (key secondary)<\/td><\/tr><tr><td><strong>Patient Population<\/strong><\/td><td>Cisplatin\u2011ineligible MIBC patients (n=564)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context-amp-outlook\">Market Context &amp; Outlook<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>Value<\/th><\/tr><\/thead><tbody><tr><td><strong>U.S. MIBC Incidence<\/strong><\/td><td>~<strong>83,000 new cases<\/strong> (2024)<\/td><\/tr><tr><td><strong>Cisplatin\u2011Ineligible Share<\/strong><\/td><td><strong>40\u201145%<\/strong> (~35,000 patients)<\/td><\/tr><tr><td><strong>Current Standard<\/strong><\/td><td>Surgery alone; no approved perioperative regimens for this population<\/td><\/tr><tr><td><strong>Peak Sales Forecast (PADCEV)<\/strong><\/td><td><strong>$2.5\u20113.5\u202fbillion<\/strong> incremental by 2030 (U.S. MIBC indication)<\/td><\/tr><tr><td><strong>Market Share Target<\/strong><\/td><td>60\u201170% of eligible patients<\/td><\/tr><tr><td><strong>Competition<\/strong><\/td><td><strong>First\u2011in\u2011class<\/strong>; no direct ADC\u2011IO competitors in perioperative setting<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Reimbursement Path:<\/strong> FDA approval enables immediate commercial access; <strong>CMS National Coverage Determination<\/strong> expected Q2\u202f2026<\/li>\n\n\n\n<li><strong>Next Catalysts:<\/strong> EU filing for MIBC indication <strong>H1\u202f2026<\/strong>; adjuvant expansion in post\u2011cystectomy patients <strong>Phase\u202fIII underway<\/strong><\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding PADCEV\u2019s commercial performance, market penetration, and regulatory expansion. Actual results may differ materially due to risks including competitive responses, reimbursement negotiations, and real\u2011world clinical adoption.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TYO: 4503) announced that the U.S. Food&#8230;<\/p>\n","protected":false},"author":1,"featured_media":49496,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[35,353,29,863,18,309,15,1177],"class_list":["post-49494","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-adc-xdc","tag-astellas-pharma","tag-combination-therapy","tag-nyse-pfe","tag-pd-1-l1","tag-pfizer","tag-product-approvals","tag-tyo-4503"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Pfizer-Astellas&#039; PADCEV Wins FDA Approval for Perioperative Bladder Cancer - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TYO: 4503) announced that the U.S. Food and Drug Administration (FDA) approved PADCEV (enfortumab vedotin) in combination with Keytruda (pembrolizumab) for perioperative treatment of adult patients with muscle\u2011invasive bladder cancer (MIBC) who are ineligible for cisplatin\u2011containing chemotherapy, based on the EV\u2011303\/KEYNOTE\u2011905 Phase\u202f3 trial showing a 60% reduction in recurrence, progression, or death risk.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=49494\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pfizer-Astellas&#039; PADCEV Wins FDA Approval for Perioperative Bladder Cancer\" \/>\n<meta property=\"og:description\" content=\"Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TYO: 4503) announced that the U.S. Food and Drug Administration (FDA) approved PADCEV (enfortumab vedotin) in combination with Keytruda (pembrolizumab) for perioperative treatment of adult patients with muscle\u2011invasive bladder cancer (MIBC) who are ineligible for cisplatin\u2011containing chemotherapy, based on the EV\u2011303\/KEYNOTE\u2011905 Phase\u202f3 trial showing a 60% reduction in recurrence, progression, or death risk.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=49494\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-29T13:59:59+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-29T14:00:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2901.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49494#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49494\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Pfizer-Astellas&#8217; PADCEV Wins FDA Approval for Perioperative Bladder Cancer\",\"datePublished\":\"2025-11-29T13:59:59+00:00\",\"dateModified\":\"2025-11-29T14:00:02+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49494\"},\"wordCount\":381,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49494#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2901.webp\",\"keywords\":[\"ADC \\\/ XDC\",\"Astellas Pharma\",\"Combination therapy\",\"NYSE: PFE\",\"PD-1\\\/L1\",\"Pfizer\",\"Product approvals\",\"TYO: 4503\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=49494#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49494\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=49494\",\"name\":\"Pfizer-Astellas' PADCEV Wins FDA Approval for Perioperative Bladder Cancer - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49494#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49494#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2901.webp\",\"datePublished\":\"2025-11-29T13:59:59+00:00\",\"dateModified\":\"2025-11-29T14:00:02+00:00\",\"description\":\"Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TYO: 4503) announced that the U.S. Food and Drug Administration (FDA) approved PADCEV (enfortumab vedotin) in combination with Keytruda (pembrolizumab) for perioperative treatment of adult patients with muscle\u2011invasive bladder cancer (MIBC) who are ineligible for cisplatin\u2011containing chemotherapy, based on the EV\u2011303\\\/KEYNOTE\u2011905 Phase\u202f3 trial showing a 60% reduction in recurrence, progression, or death risk.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49494#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=49494\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49494#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2901.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2901.webp\",\"width\":1080,\"height\":608,\"caption\":\"Pfizer-Astellas' PADCEV Wins FDA Approval for Perioperative Bladder Cancer\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49494#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pfizer-Astellas&#8217; PADCEV Wins FDA Approval for Perioperative Bladder Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Pfizer-Astellas' PADCEV Wins FDA Approval for Perioperative Bladder Cancer - Insight, China&#039;s Pharmaceutical Industry","description":"Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TYO: 4503) announced that the U.S. Food and Drug Administration (FDA) approved PADCEV (enfortumab vedotin) in combination with Keytruda (pembrolizumab) for perioperative treatment of adult patients with muscle\u2011invasive bladder cancer (MIBC) who are ineligible for cisplatin\u2011containing chemotherapy, based on the EV\u2011303\/KEYNOTE\u2011905 Phase\u202f3 trial showing a 60% reduction in recurrence, progression, or death risk.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=49494","og_locale":"en_US","og_type":"article","og_title":"Pfizer-Astellas' PADCEV Wins FDA Approval for Perioperative Bladder Cancer","og_description":"Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TYO: 4503) announced that the U.S. Food and Drug Administration (FDA) approved PADCEV (enfortumab vedotin) in combination with Keytruda (pembrolizumab) for perioperative treatment of adult patients with muscle\u2011invasive bladder cancer (MIBC) who are ineligible for cisplatin\u2011containing chemotherapy, based on the EV\u2011303\/KEYNOTE\u2011905 Phase\u202f3 trial showing a 60% reduction in recurrence, progression, or death risk.","og_url":"https:\/\/flcube.com\/?p=49494","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-11-29T13:59:59+00:00","article_modified_time":"2025-11-29T14:00:02+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2901.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=49494#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=49494"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Pfizer-Astellas&#8217; PADCEV Wins FDA Approval for Perioperative Bladder Cancer","datePublished":"2025-11-29T13:59:59+00:00","dateModified":"2025-11-29T14:00:02+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=49494"},"wordCount":381,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=49494#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2901.webp","keywords":["ADC \/ XDC","Astellas Pharma","Combination therapy","NYSE: PFE","PD-1\/L1","Pfizer","Product approvals","TYO: 4503"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=49494#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=49494","url":"https:\/\/flcube.com\/?p=49494","name":"Pfizer-Astellas' PADCEV Wins FDA Approval for Perioperative Bladder Cancer - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=49494#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=49494#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2901.webp","datePublished":"2025-11-29T13:59:59+00:00","dateModified":"2025-11-29T14:00:02+00:00","description":"Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TYO: 4503) announced that the U.S. Food and Drug Administration (FDA) approved PADCEV (enfortumab vedotin) in combination with Keytruda (pembrolizumab) for perioperative treatment of adult patients with muscle\u2011invasive bladder cancer (MIBC) who are ineligible for cisplatin\u2011containing chemotherapy, based on the EV\u2011303\/KEYNOTE\u2011905 Phase\u202f3 trial showing a 60% reduction in recurrence, progression, or death risk.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=49494#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=49494"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=49494#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2901.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2901.webp","width":1080,"height":608,"caption":"Pfizer-Astellas' PADCEV Wins FDA Approval for Perioperative Bladder Cancer"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=49494#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Pfizer-Astellas&#8217; PADCEV Wins FDA Approval for Perioperative Bladder Cancer"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2901.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/49494","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=49494"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/49494\/revisions"}],"predecessor-version":[{"id":49497,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/49494\/revisions\/49497"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/49496"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=49494"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=49494"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=49494"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}